4DMedical Secures CE Mark and A$83M Funding for European Expansion

Key Facts

14DMedical's CT:VQ™ technology received CE Mark certification for commercial use in the European Union.

2The company secured A$83 million in private placement funding to support growth initiatives.

3The new funding will be used to support commercial expansion in Europe and software development.

4DMedical Limited (ASX: 4DX) has achieved a major regulatory milestone by receiving the CE Mark certification for its CT:VQ™ imaging software. This authorization allows the company to commence commercial operations across the European Union, marking a pivotal step in its international growth strategy. Alongside this approval, the company successfully secured A$83 million in funding through a private placement to support its expansion initiatives. The proceeds are earmarked for driving commercial growth in Europe and accelerating further software development. By strengthening its balance sheet, 4DMedical is now well-positioned to execute its market entry and scale its cardiothoracic imaging technology globally. Analysts view the combination of regulatory clearance and significant capital injection as a strong bullish catalyst for the company. This dual achievement underscores 4DMedical's commitment to becoming a leader in the global MedTech landscape.